All In Biotech

Drug Trial Radar · NCT07110532

pH1N1 Blinded Challenge Study

A Double-Blinded, Randomized Influenza Virus Challenge Trial of Recombinant Influenza RG-A/Arkansas/08/2020 (pH1N1) in Healthy Adults to Assess Safety and Optimal Infectious Dose

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Sep 10, 2025

Primary completion

Mar 29, 2027

Study completion Mar 29, 2027

Sponsor

Sponsor type
NIH
First posted
Aug 7, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This protocol describes a clinical trial to develop and validate a Controlled Human Infection Model (CHIM) for influenza A/Arkansas/08/2020 (pH1N1). The study is designed to determine the optimal infectious dose of the pH1N1 challenge strain for use in future clinical trials evaluating influenza countermeasures. The study will enroll and challenge adult volunteers with the pH1N1 influenza virus challenge or sham inoculations. Given the adaptive design of this trial, the potential number of participants can vary. Depending on the pathway recommended by the PSRT and followed in the Trial Schema, the study population can range from around 30 to 99. The anticipated final sample size will be approximately 90 receiving pH1N1 challenge product plus and 6 persons receiving a sham inoculation. Participants will be pre-screened for health and for serological HAI antibody titers of \</1:40 against the challenge strain. Eligible participants will be enrolled sequentially into challenge cohorts and will be randomly assigned to receive a single dose of either sham inoculation or the interventional study product at a dose between 10\^6 to 10\^7 TCID50 (or 10\^5 TCID50 if needed). Dose titration will be conducted under an adaptive escalation schedule whereby dosing will start at 10\^6 TCID50 and escalate to the next dose if a pre-determined symptomatic influenza attack rate and clinical symptom score thresholds are not met and if the dose is determined to be safe with no pre-defined halting criteria being met. The primary objectives of this study are to determine the optimal infectious dose of a pH1N1 viral challenge to cause laboratory-confirmed clinical influenza and to assess the safety profile of pH1N1 viral challenge.

Conditions

  • Influenza

Interventions

  • A/Arkansas/08/2020 (pH1N1)Biological

    GMP-grade, cell-based influenza A (pH1N1) virus (Lot #24-005), derived via reverse genetics for use in controlled human infection studies.

  • Sham/Diluent (1X SPG+Arg+Gel)Other

    Sterile diluent containing 1X Sucrose Phosphate Glutamate (SPG), 1% arginine, and 1% hydrolyzed gelatin, used as a sham comparator in the human challenge trial.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number and percentage of participants reporting a related SAE at any time from the time of the first challenge inoculation.Time frame: Through Day 57
  2. Number and percentage of participants reporting any related AE from the time of the first challenge inoculation.Time frame: Through Day 29
  3. Number and percentage of participants with symptomatic influenza virus infection.Time frame: Day 2 through Day 6
  4. Number of related adverse events (AE) reported from the time of the first challenge inoculation.Time frame: Through Day 29
  5. Number of related serious adverse events (SAE) from the time of the first challenge inoculation.Time frame: Through Day 57

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • University of Maryland, School of Medicine, Center for Vaccine Development and Global Health

    Baltimore, Maryland · Recruiting

  • Duke Vaccine and Trials Unit

    Durham, North Carolina · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.